Vertex, Verve team up to develop a gene editing drug for liver disease

Bio Pharma Dive

The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease

FDA sets out advice to developers of gene editing medicines

Bio Pharma Dive

Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer expands into gene editing with Beam research deal

Bio Pharma Dive

Pfizer's work with mRNA vaccines led it explore other applications of the technology, resulting in a multi-year partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases

Vertex aligns with another CRISPR gene editing startup

Bio Pharma Dive

A new alliance with Mammoth Biosciences marks the latest evidence of Vertex's interest in gene editing, which has already been the focus of multiple deals with emerging biotechs

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Bio Pharma Dive

Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's

Moderna, teaming with a startup, wades further into gene editing

Bio Pharma Dive

The biotech has identified gene editing as a natural fit for the technology it uses to deliver its vaccines and drugs. A deal with Metagenomi, a startup backed by Bayer, will further those ambitions

Beam, Apellis partner in deal to expand gene editing's reach

Bio Pharma Dive

The companies aim to develop therapies for complement-driven diseases, a specialty of Apellis and relatively new research ground for gene editing

Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods

Bio Pharma Dive

The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance

Gene editing biotechs face new uncertainty after CRISPR patent ruling

Bio Pharma Dive

A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California

Vertex, CRISPR strengthen case for pioneering gene-editing treatment

Bio Pharma Dive

Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year

Intellia, with first results, delivers a 'landmark' for CRISPR gene editing

Bio Pharma Dive

Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research

Caribou raises $304M in one of gene editing's most lucrative IPOs

Bio Pharma Dive

The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam

Lilly dives into gene editing

Bio Pharma Dive

Through a deal with Precision Biosciences, the pharma aims to develop therapies for genetic disorders, including Duchenne muscular dystrophy

Gene editing: beyond the hype

Pharma Phorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Zinc fingers are the most common control gene in the body,” Macrae explains. “We Gene therapy can ultimately only take you into the liver,” he explains.

Verve starts first human test of gene editing treatment for heart disease

Bio Pharma Dive

A patient in New Zealand became the first person to receive the biotech’s medicine, which uses base editing to turn off a specific gene in the liver and thereby lower cholesterol

Gene editing startup Metagenomi raises $175M to advance research pipeline

Bio Pharma Dive

The biotech raised the Series B round during "probably one of the worst biotech markets" emerging drugmakers have faced in some time, a Metagenomi executive told BioPharma Dive

AbbVie exploring how CRISPR gene editing can improve cell therapies

Bio Pharma Dive

Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system

Who trusts gene-edited foods? New study gauges public acceptance

Scienmag

AMES, IA – Through CRISPR and other gene-editing technologies, researchers and developers are poised to bring dozens – if not hundreds – of new products to grocery stores: mushrooms with longer shelf lives, drought-resistant corn and bananas impervious to a fungus threatening the global supply.

After long wait, Editas reveals first data for CRISPR gene editing treatment

Bio Pharma Dive

Early study results offer some hopeful signs of efficacy, but the small number of patients treated and short follow-up limit firmer conclusions

EHA: Vertex, CRISPR build case for gene-editing drug

Pharma Phorum

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease.

Gene-Editing the Microbiome: The Limitless Possibilities

BioSpace

Eligo Bioscience has thought of a way to solve the dysbiosis between our bodies and our microbiomes – gene editing. BioSpace spoke with Eligo Co-founder and CEOXavier Duportet, Ph.D.

CRISPR gene editing reveals biological mechanism behind common blood disorder

Scienmag

UNSW researchers have used CRISPR gene editing – a type of ‘molecular scissors’ – to understand how deletions in one area of the genome can affect the expression of nearby genes. Biology biological blood common CRISPR disorder editing gene mechanism reveals

Gene-editing used to create single sex mice litters

Scienmag

Prime Medicine raises $315M to fuel 'search-and-replace' gene editing work

Bio Pharma Dive

Formed around research from the Broad Institute's David Liu and Andrew Anzalone, Prime has attracted significant funding from a wide range of high-profile biotech backers

Pushing Beyond Gene Editing Limits with Programmable RNA Medicines

BioSpace

Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss

A CRISPR gene editing treatment continues to show promise for two blood diseases

Bio Pharma Dive

Results from 10 patients with beta thalassemia or sickle cell disease show CRISPR Therapeutics and Vertex's pioneering treatment to be effective, building on earlier study data

JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's and Pfizer's deep pockets

Bio Pharma Dive

Verve, a buzzy gene editing startup, unveiled its first drug candidate on Tuesday, while Eli Lilly's and Pfizer's CEO gave updates on Alzheimer's and dealmaking

Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes

Bio Pharma Dive

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership

Bayer and Mammoth Biosciences collaborate on novel gene editing tech

BioPharma Reporter

have announced a strategic collaboration and option agreement for the use of Mammothâs CRISPR systems to develop in vivo gene-editing therapies. Bayer AG and Mammoth Biosciences, Inc.,

CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder

Bio Pharma Dive

A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Bio Pharma Dive

A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others

#news #biotech Research team improves gene editing with chemical process

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Research team improves gene editing with chemical process.The gene-editing technique known as CRISPR has accelerated biological and medical research in the last decade by allowing scientists to … Continue reading → #news

Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline

Bio Pharma Dive

The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research

Medicine of the Future Happening Today - Seelos Sees Promise for In Vivo Gene Editing

BioSpace

This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures

Will Intellia Make Gene Editing History Saturday?

BioSpace

In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body

Bringing in Light Genome Editing Techniques: ZFN, TALEN and Meganucleases

Roots Analysis

Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. Genome Editing is a way of making changes in the DNA.

Gene-edited cell replacement therapy for diabetes set to enter the clinic

BioPharma Reporter

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Scientists put CRISPR on safer path to patient treatments with new process for evaluating impacts of gene edits that alter rather than “knock out” DNA code

Scienmag

Medicine & Health alter code CRISPR DNA edits evaluating gene impacts knock path patient process put Safer scientists treatments

DNA 71

#news #biotech A potential danger of CRISPR gene editing—and why base editing may be safer

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: A potential danger of CRISPR gene editing—and why base editing may be safer.Gene therapy using CRISPR/Cas9 gene editing is currently in clinical trials around the world for … Continue reading → #news

Gene editing DNA deletion sizes reduced with new fusion method developed at WFIRM

Scienmag

WINSTON-SALEM, NC – May 2, 2022 — Wake Forest Institute for Regenerative Medicine (WFIRM) scientists working on CRISPR/Cas9-mediated gene editing technology have developed a method to increase efficiency of editing while minimizing DNA deletion sizes, a key step toward developing gene editing therapies to treat genetic diseases. Latest News deletion developed DNA editing fusion gene method reduced sizes WFIRM

Moderna Moves Into Gene Editing Space with Metagenomi R&D Collab

BioSpace

The partnership will leverage Metagenomi’s novel gene editing technology and Moderna’s mRNA platform, in addition to its lipid nanoparticle delivery technologies

#news #biotech Who trusts gene-edited foods? New study gauges public acceptance

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Who trusts gene-edited foods? New study gauges public acceptance.Through CRISPR and other gene-editing technologies, researchers and developers are poised to bring dozens—if not hundreds—of new products to … Continue reading → #news

Gene Editing Breakthroughs Accelerate Heart, Stroke Research

BioSpace

?Gene therapy research delivers breakthroughs this week with a CRISPR-edited droplet that could lead to a cure for heart disease and the possibility of turning glial brain cells into neurons